Breaking News, Financial News

Financial Report: Genentech 4Q

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Genentech 4Q Revenues: $3.7 billion (+25%) 4Q Earnings: $931 million (+14%) FY Revenues: $13.4 billion (+14%) FY Earnings: $3.4 billion (+24%) Comments: U.S. product sales were $2.5 million in the quarter (+13%) and up 11% to $9.5 million for the year. Avastin sales were $731 million in the quarter (+21%) and $2.7 billion for the year (+17%). Rituxan sales were $677 million in the quarter (+14%) and $2.6 billion for the year (+13%). Herceptin sales were $337 million in the quarter...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters